Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing real-world study of Zhixue Quyu Mingmu Tablet for submacular hemorrhage
ChiCTR2000035098Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2019
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zhixue quyu mingmu in submacular hemorrhage (SMH), sponsored by Peking Union Medical College Hospital. Primary endpoint: Vision improvement within 6 months. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
zhixue quyu mingmu
03
Conditions
submacular hemorrhage (SMH)
Beyond the preview
Go deeper on ChiCTR2000035098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035098.